On October 31, 2012, the Company filed a Form 8-K in connection with its entering into a License Agreement, dated as of October 26, 2012 (the "License Agreement"), with BioMarin Pharmaceutical, Inc. ("BioMarin"). This Form 8-K/A amends the original Form 8-K as filed to file another redacted copy of the License Agreement pursuant to the Company's request for confidential treatment with the Securities and Exchange Commission.

(d) Exhibits

10.1    License Agreement, dated as of October 26, 2012, between BioMarin
        Pharmaceutical, Inc. and Catalyst Pharmaceutical Partners, Inc. (portions
        of this exhibit have been omitted and filed separately with the Securities
        and Exchange Commission pursuant to a request for confidential treatment.)